Should I buy or sell Ambrx Biopharma stock right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Ambrx Biopharma in the last twelve months. There are currently 4 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" AMAM shares. View AMAM analyst ratings or view top-rated stocks .

What is Ambrx Biopharma's stock price target for 2024?

8 brokers have issued twelve-month price targets for Ambrx Biopharma's shares. Their AMAM share price targets range from $9.00 to $32.00. On average, they anticipate the company's share price to reach $24.13 in the next year. This suggests that the stock has a possible downside of 13.8%. View analysts price targets for AMAM or view top-rated stocks among Wall Street analysts .

What ETF holds Ambrx Biopharma's stock?

AltShares Merger Arbitrage ETF holds 42,594 shares of AMAM stock, representing 1.95% of its portfolio.

When did Ambrx Biopharma IPO?

Ambrx Biopharma (AMAM) raised $126 million in an IPO on Friday, June 18th 2021. The company issued 7,000,000 shares at $17.00-$19.00 per share. Goldman Sachs, BofA Securities and Cowen served as the underwriters for the IPO.

NYSE:AMAM

Ambrx Biopharma (AMAM) Stock Price, News & Analysis

→ SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad)

Free AMAM Stock Alerts

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: $28.00
▼
$28.00
50-Day Range: $27.70
▼
$28.00
52-Week Range: $6.55
▼
$28.15

Volume: N/A
Average Volume: 2.12 million shs
Market Capitalization: $1.77 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $24.13

Stock Analysis Analyst Forecasts Earnings Headlines Insider Trades Ownership Social Media

Get Ambrx Biopharma alerts:

Ambrx Biopharma MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.50 Rating Score
Upside/Downside: 13.8% Downside
$24.13 Price Target
Short Interest: N/A
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($1.45) to ($1.28) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.08 out of 5 stars

Medical Sector

905th out of 912 stocks

Biological Products, Except Diagnostic Industry

148th out of 149 stocks

1.3

Analyst's Opinion

Consensus Rating
Ambrx Biopharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 4 buy ratings, 4 hold ratings, and no sell ratings.
Amount of Analyst Coverage
Ambrx Biopharma has received no research coverage in the past 90 days.

N/A

Short Interest

Short Interest
There is no current short interest data available for AMAM.

0.0

Dividend Strength

Dividend Yield
Ambrx Biopharma does not currently pay a dividend.
Dividend Growth
Ambrx Biopharma does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for AMAM.

0.6

News and Social Media Coverage

Search Interest
5 people have searched for AMAM on MarketBeat in the last 30 days. This is an increase of 25% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Ambrx Biopharma insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 0.64% of the stock of Ambrx Biopharma is held by insiders.
Percentage Held by Institutions
77.28% of the stock of Ambrx Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Ambrx Biopharma are expected to grow in the coming year, from ($1.45) to ($1.28) per share.
Price to Book Value per Share Ratio
Ambrx Biopharma has a P/B Ratio of 9.18. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

About Ambrx Biopharma Stock (NYSE:AMAM)

Ambrx Biopharma Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing antibody drug conjugates (ADCs) and other engineered therapies to modulate the immune system. It focuses on portfolio of clinical and preclinical programs designed to optimize efficacy and safety in multiple cancer indications, including ARX517, its proprietary antibody-drug conjugate (ADC) targeting the prostate-specific membrane antigen (PSMA) and ARX788, its proprietary ADC targeting HER2. The company also has preclinical and clinical collaborations with multiple partners on drug candidates using Ambrx technology. The company was incorporated in 2003 and is headquartered in La Jolla, California.

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

AMAM Stock News Headlines

April 5, 2024 | benzinga.com

Latest News for Johnson & Johnson Stock (NYSE:JNJ)

March 7, 2024 | finanznachrichten.de

Ambrx Biopharma Inc.: Ambrx Shareholders Approve Acquisition by Johnson & Johnson

April 20, 2024 | Crypto 101 Media (Ad)

SHOCKING Crypto Leak…

A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.

March 7, 2024 | markets.businessinsider.com

Johnson & Johnson Buys Ambrx Biopharma In $2 Bln Cash Deal

March 6, 2024 | globenewswire.com

Ambrx Shareholders Approve Acquisition by Johnson & Johnson

February 23, 2024 | investorplace.com

3 Stocks to Buy That Are Up 200% or More in 2024

February 20, 2024 | msn.com

Is Ambrx Biopharma Inc. (AMAM) Stock Outpacing Its Medical Peers This Year?

February 12, 2024 | stockhouse.com

SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates DOOR, CBAY, WISH, AMAM

April 20, 2024 | Crypto 101 Media (Ad)

SHOCKING Crypto Leak…

February 10, 2024 | businesswire.com

AMBRX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Ambrx Biopharma, Inc. - AMAM

January 20, 2024 | stockhouse.com

SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates AXNX, AMAM, HARP

January 11, 2024 | msn.com

JMP Securities Downgrades Ambrx Biopharma (AMAM)

January 10, 2024 | realmoney.thestreet.com

Ambrx Biopharma just downgraded at JMP Securities, here's why

January 9, 2024 | finance.yahoo.com

Ambrx (AMAM) Skyrockets 102% on $2B Buyout Offer From J&J

January 8, 2024 | nasdaq.com

J&J to buy cancer therapy developer Ambrx for $2 bln

January 8, 2024 | tmcnet.com

AMAM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Ambrx Biopharma, Inc. Is Fair to Shareholders

January 8, 2024 | markets.businessinsider.com

Crude Oil Falls Sharply; Ambrx Biopharma Shares Spike Higher

January 8, 2024 | investorplace.com

Why Is Ambrx Biopharma (AMAM) Stock Up 100% Today?

January 8, 2024 | reuters.com

Johnson & Johnson to buy Ambrx Biopharma for $2 bln

January 8, 2024 | finance.yahoo.com

Ambrx Announces Sale to Johnson & Johnson

December 14, 2023 | msn.com

Ambrix to Join NASDAQ Biotech Index

December 14, 2023 | finance.yahoo.com

Ambrx to be Added to the NASDAQ Biotechnology Index (NBI)

November 29, 2023 | markets.businessinsider.com

Optimistic Outlook on Ambrx Biopharma’s Pipeline Justifies Buy Rating

November 28, 2023 | finance.yahoo.com

Ambrx Provides Update On APEX-01, an On-Going Phase 1 / 2 Dose Escalation Study Evaluating ARX517, a Proprietary PSMA-Targeting ADC, in Metastatic Castration-Resistant Prostate Cancer

November 18, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Twist Bioscience (TWST) and Ambrx Biopharma (AMAM)

November 14, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Ambrx Biopharma (AMAM) and Viridian Therapeutics (VRDN)

November 14, 2023 | markets.businessinsider.com

Goldman Sachs Keeps Their Hold Rating on Ambrx Biopharma (AMAM)

See More Headlines

Receive AMAM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ambrx Biopharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today: 4/19/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSE
Sector: Medical
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Current Symbol: NYSE:AMAM
CUSIP: N/A
CIK: 1836056
Web: ambrx.com
Phone: 858-875-2400
Fax: N/A
Employees: 87
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $24.13
High Stock Price Target: $32.00
Low Stock Price Target: $9.00
Potential Upside/Downside: -13.8%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.50
Research Coverage: 8 Analysts

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 13.28
Quick Ratio: 13.28

Sales & Book Value

Annual Sales: $7.40 million
Price / Sales: 238.95
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.05 per share
Price / Book: 9.18

Miscellaneous

Outstanding Shares: 63,150,000
Free Float: 62,746,000
Market Cap: $1.77 billion
Optionable: Optionable
Beta: -1.92

13 Stocks Institutional Investors Won't Stop Buying

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

Mr. Daniel J. O'Connor J.D. (Age 59)
CEO, President & Director
Comp: $509.94k
Ms. Sonja Nelson CPA (Age 51)
Chief Financial Officer
Comp: $1.18M
Mr. Andrew P. Aromando (Age 55)
Chief Operating Officer
Dr. Ying J. Buechler Ph.D.
Chief Technology Officer
Dr. Shawn Shao-Hui Zhang Ph.D.
Chief Scientific Officer & GM of China
Mr. Jared Kelly
Senior VP, General Counsel & Corporate Secretary
Mr. Robert Azzara
Vice President of Human Capital
Dr. Sandra Aung Ph.D.
Chief Clinical Officer
Ms. Renu Vaish M.Sc. (Age 57)
Chief Regulatory Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

AMAM Stock Analysis - Frequently Asked Questions

Should I buy or sell Ambrx Biopharma stock right now?: 8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Ambrx Biopharma in the last twelve months. There are currently 4 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" AMAM shares.
View AMAM analyst ratings or view top-rated stocks.
What is Ambrx Biopharma's stock price target for 2024?: 8 brokers have issued twelve-month price targets for Ambrx Biopharma's shares. Their AMAM share price targets range from $9.00 to $32.00. On average, they anticipate the company's share price to reach $24.13 in the next year. This suggests that the stock has a possible downside of 13.8%.
View analysts price targets for AMAM or view top-rated stocks among Wall Street analysts.
What ETF holds Ambrx Biopharma's stock?: AltShares Merger Arbitrage ETF holds 42,594 shares of AMAM stock, representing 1.95% of its portfolio.
When did Ambrx Biopharma IPO?: Ambrx Biopharma (AMAM) raised $126 million in an IPO on Friday, June 18th 2021. The company issued 7,000,000 shares at $17.00-$19.00 per share. Goldman Sachs, BofA Securities and Cowen served as the underwriters for the IPO.

This page (NYSE:AMAM) was last updated on 4/20/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Ambrx Biopharma (AMAM) Stock Price, News & Analysis